Vanda's tradipitant meets in Phase II for gastroparesis

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) said tradipitant met the primary endpoint in the Phase II VLY-686-2301 trial to

Read the full 177 word article

User Sign In